To explore the clinical efficacy and safety of Oxaliplatin combined with transcatheter arterial chemoembolization in the treatment of elderly patients with primary hepatocellular carcinoma.

One-hundred and three elderly patients with primary hepatocellular carcinoma who were treated in First Affiliated Hospital of Bengbu Medical College from January 2013 to July 2017 were selected. Based on the treatment methods, all patients were divided into the observation group and the control group by random number table method. Patients in the observation group (n=51) were treated with transcatheter arterial chemoembolization combined with Oxaliplatin, and those in the control group (n=52) treated with traditional hepatic arterial chemoembolization. The clinical efficacy and adverse reactions were compared and analyzed between groups.

In the observation group, the partial remission rate (70.6% vs. 50%, χ²=4.555, P=0.033) and the total effective rate (72.6% vs. 50%, χ²=5.511, P=0.019) were significantly higher than those in the control group. Additionally, there was no significant difference in the incidence of adverse reactions between the two groups (all P>0.05).

Combined with transcatheter arterial chemoembolization, Oxaliplatin could safely and effectively improve the prognosis of elderly patients with primary hepatocellular carcinoma..

Oembolization, therapeutic; Liver neoplasms